A Pilot Study Using Neoadjuvant Proton Beam Radiation Therapy and Chemotherapy for Marginally Resectable Carcinoma of the Pancreas.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Nov 2016
At a glance
- Drugs Capecitabine (Primary) ; Gemcitabine (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- 17 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 14 Mar 2013 Planned end date changed from 1 Sep 2050 to 1 Sep 2040 as reported by ClinicalTrials.gov.
- 05 Mar 2012 Planned end date changed from 1 Sep 2018 to 1 Sep 2050 as reported by ClinicalTrials.gov.